Your browser doesn't support javascript.
loading
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Deininger, Michael W; Hodgson, J Graeme; Shah, Neil P; Cortes, Jorge E; Kim, Dong-Wook; Nicolini, Franck E; Talpaz, Moshe; Baccarani, Michele; Müller, Martin C; Li, Jin; Parker, Wendy T; Lustgarten, Stephanie; Clackson, Tim; Haluska, Frank G; Guilhot, Francois; Kantarjian, Hagop M; Soverini, Simona; Hochhaus, Andreas; Hughes, Timothy P; Rivera, Victor M; Branford, Susan.
Afiliação
  • Deininger MW; Huntsman Cancer Institute University of Utah, Salt Lake City, UT;
  • Hodgson JG; ARIAD Pharmaceuticals, Inc., Cambridge, MA;
  • Shah NP; University of California San Francisco, San Francisco, CA;
  • Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Kim DW; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea;
  • Nicolini FE; Centre Hospitalier Lyon Sud, Pierre Benite, & INSERM U1052, Lyon, France;
  • Talpaz M; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI;
  • Baccarani M; Department of Hematology-Oncology "L. and A. Seragnoli," S. Orsola-Malpighi University Hospital, Bologna, Italy;
  • Müller MC; III. Med. Klinik, Universitätsmedizin Mannheim, Mannheim, Germany;
  • Li J; MolecularMD, Portland, OR;
  • Parker WT; Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and.
  • Lustgarten S; ARIAD Pharmaceuticals, Inc., Cambridge, MA;
  • Clackson T; ARIAD Pharmaceuticals, Inc., Cambridge, MA;
  • Haluska FG; ARIAD Pharmaceuticals, Inc., Cambridge, MA;
  • Guilhot F; INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, France;
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Soverini S; Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy;
  • Hochhaus A; Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany;
  • Hughes TP; SA Pathology and South Australian Health and Medical Research Institute, Adelaide, Australia; Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and.
  • Rivera VM; ARIAD Pharmaceuticals, Inc., Cambridge, MA;
  • Branford S; Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.
Blood ; 127(6): 703-12, 2016 Feb 11.
Article em En | MEDLINE | ID: mdl-26603839
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridazinas / Leucemia Mieloide de Fase Crônica / Proteínas de Fusão bcr-abl / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Imidazóis / Mutação Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridazinas / Leucemia Mieloide de Fase Crônica / Proteínas de Fusão bcr-abl / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Imidazóis / Mutação Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2016 Tipo de documento: Article